Efficacy and safety of crizotinib in patients with advanced <i>ROS1</i>-rearranged non-small cell lung cancer (NSCLC).
Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Alice T. Shaw(Dana-Farber Cancer Institute), Jeffrey A. Engelman(Cancer Research Center), Geoffrey I. Shapiro(Brigham and Women's Hospital), Benjamin Solomon(Peter MacCallum Cancer Centre), Kristin Bergethon(Massachusetts General Hospital), Yung‐Jue Bang(Seoul National University), L. Tye(Pfizer (United States)), A. John Iafrate(Massachusetts General Hospital), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Keith D. Wilner(Pfizer (United States)), D. Ross Camidge(University of Colorado Denver), Jeffrey W. Clark(Massachusetts General Hospital), Patricia Stephenson(Rho (United States)), Ravi Salgia(City Of Hope National Medical Center), Eunice L. Kwak(Harvard University), Marileila Varella‐Garcia(University of Colorado Anschutz Medical Campus)
Cited by 62
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k